1/2 @WaldoGMed @nyphospital to present Posterior Approach to Total Endopelvic Neurovascular Total Sparing (PATENTS) @UroOnc #SUO2025. @brady_urology. Dr Patrick Walsh (with permission) contrasts his RRP high release vs Menon Veil of Aphrodite as ref to PATENTS - @JUOpenPlus soon

Pooling PREVENT 1 AND PREVENT 2 RCTs demonstrated no difference in cancer detection or prevalence of anterior tumor location using TP vs TR biopsy for Black men vs. others: Association Between Race and Detection of Clinically Significant PCa https://t.co/63qr6JdcT1

Alliance researcher @eugene_pietzak @MSKCancerCenter leads @ALLIANCE_org A032303/GAIN-BCG, a trial evaluating a two-step treatment approach for pts w/BCG-unresponsive non–muscle-invasive #bladdercancerome. Learn more: https://t.co/mjpt3I0t2n #NCI #NCTN #CancerResearch #NMIBC

👀comprehensive review (and table) of RCTs for Transperineal vs transrectal prostate biopsy by super⭐️@EvanSuzman @UTSWMedCenter MS4 @nyphospital @WeillCornell @WCMUrology Review of Transperineal and Transrectal Prostate Biopsy Outcomes https://t.co/U0ib5Ix8Q9

Pelvic fascia‑sparing during RARP improves urinary continence recovery 🧬 Posterior PFS: 90% @3 mo, 96% @12 mo, 97% @20 mo 🧠 Anterior PFS: 83% @3 mo, 89% @12 mo, 99% @20 mo 🔬 Both techniques ~3.5‑fold ↑ continence at 3 mo; only posterior PFS sustained benefit at 20 mo

👀 ⭐️@WaldoGMed @nyphospital @KeithKow @GUUrology 10th @EUplatinum journals Surgery in Motion. Largest comparison of Hood, Retzius vs Std Robotic RP: Retzius>Hood>Std continence recovery, but ⬆️ Retzius + SMs https://t.co/KsFVOmOgeO

Congratulations to our current chief residents, Drs. Lina Posada Calderon & Oakley Strasser on their urologic oncology fellowship matches! We are so proud of all you have accomplished throughout your residency, and we wish you luck as you both begin your fellowships next year!

Thank you for the wonderful year @jimhumd Incredible way to round it out and begin PGY5

Humbled and honored to be among this year’s @ConquerCancerFd YIA grant recipients. Indebted to my mentors — Dr. @eugene_pietzak , Dr. @IyerGopa , and the team at @UrologyMSK @MSKCancerCenter — for their unwavering guidance and support. Excited for the future #ASCO25

Jim C. Hu, MD, (@jimhumd) details findings from a study comparing urinary continence recovery across standard, Retzius-sparing, and Hood RARP techniques. #AUA25 @WCMUrology https://t.co/596oEWBq6h

Highlights from #SUO24! @AmyLuckenbaugh @VUMChealth & @UroCancerMD @VUMCurology dive into late-breaking #bladdercancer trials—combo intravesical gem/BCG for BCG-exposed & phase III cretostimogene in BCG-unresponsive CIS. Key takeaway? More options than ever for #NMIBC, with

Studies and clinical trials related to decision-making insights and market demand for early infant male circumcision with ShangRing in Kenya, Tanzania, and Uganda received great attention at the 2025 AUA. @LinaPosadaCald and @ @WaldoGMed did an excellent job showcasing our work

Recovery of urinary continence after robotic-assisted radical prostatectomy: A multicenter comparison of Retzius-sparing, hood, and standard techniques. Presented by @WaldoGMed @WCMUrology. #AUA25 written coverage by @zklaassen_md @GACancerCenter on UroToday >

Congratulations to Aaron Gurayah, MD (@AGurayah), PGY2 resident, for winning best poster for his research on barriers to prostate cancer screening under the mentorship of Dr. Meena Davuluri (@MeenaDavuluri) at #AUA25! We are so proud of you!

We are so excited for #AUA25 to begin in few weeks! Our faculty, fellows and residents are looking forward to participating in a variety of sessions as well as connecting with colleagues. Scroll⏬ to learn more about what our trainees will be presenting during the meeting.

Comparative outcomes of intralesional #collagenase injection for #PeyroniesDisease: acute vs. stable phase treatment👉 https://t.co/ScA4uAiwdE @manishkuch @nyphospital @WeillCornell @HBhambhvani @WCMUrology @WaldoGMed

Phase II trial explores gemcitabine + BCG for BCG-exposed #BladderCancer. @eugene_pietzak @MSKCancerCenter & @WaldoGMed @WCMUrology join @UroCancerMD @VUMCurology to discuss this phase II trial that demonstrates promising results with a 94% complete response rate at six months

Fun to get together with the talented and dedicated @nyphospital @WCMUrology residents!

@ASCO #GU25 Poster Session #BladderCancer @UrologyMSK @UroMuneeb @eugene_pietzak E6- The impact of micropapillary histology and clinical staging on OS ✨130 pts ✨Presence of micropappillary predicts poor prognosis, regardless of its proportion ‼️ 👉The key predictor of

Video in @UroToday: @UroCancerMD chats with @waldogmed and @eugene_pietzak about intravesical gemcitabine and BCG combination therapy for BCG-exposed non-muscle-invasive bladder cancer. Click to watch the video: